214 related articles for article (PubMed ID: 35459782)
1. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Odeniyide P; Yohe ME; Pollard K; Vaseva AV; Calizo A; Zhang L; Rodriguez FJ; Gross JM; Allen AN; Wan X; Somwar R; Schreck KC; Kessler L; Wang J; Pratilas CA
Oncogene; 2022 May; 41(21):2973-2983. PubMed ID: 35459782
[TBL] [Abstract][Full Text] [Related]
2. Tipifarnib as a Precision Therapy for
Gilardi M; Wang Z; Proietto M; Chillà A; Calleja-Valera JL; Goto Y; Vanoni M; Janes MR; Mikulski Z; Gualberto A; Molinolo AA; Ferrara N; Gutkind JS; Burrows F
Mol Cancer Ther; 2020 Sep; 19(9):1784-1796. PubMed ID: 32727882
[TBL] [Abstract][Full Text] [Related]
3. Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.
Javaid S; Schaefer A; Goodwin CM; Nguyen VV; Massey FL; Pierobon M; Gambrell-Sanders D; Waters AM; Lambert KN; Diehl JN; Hobbs GA; Wood KC; Petricoin EF; Der CJ; Cox AD
Mol Cancer Ther; 2022 May; 21(5):762-774. PubMed ID: 35247914
[TBL] [Abstract][Full Text] [Related]
4. The chaperone SmgGDS-607 has a dual role, both activating and inhibiting farnesylation of small GTPases.
García-Torres D; Fierke CA
J Biol Chem; 2019 Aug; 294(31):11793-11804. PubMed ID: 31197034
[TBL] [Abstract][Full Text] [Related]
5. Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence.
Li JJ; Kovach AR; DeMonia M; Slemmons KK; Oristian KM; Chen C; Linardic CM
Sci Rep; 2021 Aug; 11(1):16505. PubMed ID: 34389744
[TBL] [Abstract][Full Text] [Related]
6. Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise.
Desilets A; Ho AL
Cancer J; 2022 Sep-Oct 01; 28(5):363-368. PubMed ID: 36165724
[TBL] [Abstract][Full Text] [Related]
7. Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.
Untch BR; Dos Anjos V; Garcia-Rendueles MER; Knauf JA; Krishnamoorthy GP; Saqcena M; Bhanot UK; Socci ND; Ho AL; Ghossein R; Fagin JA
Cancer Res; 2018 Aug; 78(16):4642-4657. PubMed ID: 29760048
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
9.
Dolgikh N; Hugle M; Vogler M; Fulda S
Cancer Res; 2018 Apr; 78(8):2000-2013. PubMed ID: 29437705
[TBL] [Abstract][Full Text] [Related]
10. Frequent HRAS Mutations in Malignant Ectomesenchymoma: Overlapping Genetic Abnormalities With Embryonal Rhabdomyosarcoma.
Huang SC; Alaggio R; Sung YS; Chen CL; Zhang L; Kao YC; Agaram NP; Wexler LH; Antonescu CR
Am J Surg Pathol; 2016 Jul; 40(7):876-85. PubMed ID: 26872011
[TBL] [Abstract][Full Text] [Related]
11. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
Alsina M; Fonseca R; Wilson EF; Belle AN; Gerbino E; Price-Troska T; Overton RM; Ahmann G; Bruzek LM; Adjei AA; Kaufmann SH; Wright JJ; Sullivan D; Djulbegovic B; Cantor AB; Greipp PR; Dalton WS; Sebti SM
Blood; 2004 May; 103(9):3271-7. PubMed ID: 14726402
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
13. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic and survival correlates of embryonal rhabdomyosarcoma driven by RAS/RAF mutations.
Agaram NP; Huang SC; Tap WD; Wexler LH; Antonescu CR
Genes Chromosomes Cancer; 2022 Mar; 61(3):131-137. PubMed ID: 34755412
[TBL] [Abstract][Full Text] [Related]
15. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.
Yonemoto M; Satoh T; Arakawa H; Suzuki-Takahashi I; Monden Y; Kodera T; Tanaka K; Aoyama T; Iwasawa Y; Kamei T; Nishimura S; Tomimoto K
Mol Pharmacol; 1998 Jul; 54(1):1-7. PubMed ID: 9658183
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcoma.
Nakagawa N; Kikuchi K; Yagyu S; Miyachi M; Iehara T; Tajiri T; Sakai T; Hosoi H
Biochem Biophys Res Commun; 2019 May; 512(3):524-530. PubMed ID: 30904164
[TBL] [Abstract][Full Text] [Related]
17. Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Smith AE; Chan S; Wang Z; McCloskey A; Reilly Q; Wang JZ; Patel HV; Koshizuka K; Soifer HS; Kessler L; Dayoub A; Villaflor V; Adkins DR; Bruce JY; Ho AL; Perez CA; Hanna GJ; Gascó Hernández A; Saunders A; Dale S; Gutkind JS; Burrows F; Malik S
Cancer Res; 2023 Oct; 83(19):3252-3263. PubMed ID: 37339176
[TBL] [Abstract][Full Text] [Related]
18. RAS signaling dysregulation in human embryonal Rhabdomyosarcoma.
Martinelli S; McDowell HP; Vigne SD; Kokai G; Uccini S; Tartaglia M; Dominici C
Genes Chromosomes Cancer; 2009 Nov; 48(11):975-82. PubMed ID: 19681119
[TBL] [Abstract][Full Text] [Related]
19. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
[TBL] [Abstract][Full Text] [Related]
20. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
